Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook

[1]  N. Satake,et al.  Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia. , 2013, Leukemia research.

[2]  M. Tsubokura,et al.  Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin , 2013, Investigational New Drugs.

[3]  R. O’Donnell,et al.  Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin’s lymphoma , 2012, Oncoimmunology.

[4]  P. Moreau,et al.  Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial , 2012 .

[5]  R. Elstrom,et al.  Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results , 2012 .

[6]  D. Gandara,et al.  CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy. , 2012, Cancer research.

[7]  Kerry A Chester,et al.  Antibody–drug conjugates – a perfect synergy , 2012, Expert opinion on biological therapy.

[8]  D. Elbirt,et al.  Novel biological treatments for systemic lupus erythematosus: current and future modalities. , 2012, The Israel Medical Association journal : IMAJ.

[9]  W. Wilson,et al.  Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  I. Pastan,et al.  Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy , 2012, Proceedings of the National Academy of Sciences.

[11]  H. Kantarjian,et al.  Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. , 2012, The Lancet Oncology.

[12]  A. Saven,et al.  Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22 , 2012, Leukemia & lymphoma.

[13]  L. Zitvogel,et al.  OncoImmunology: a new journal at the frontier between oncology and immunology , 2012, Oncoimmunology.

[14]  Julia Jellusova,et al.  Regulation of B Cell Functions by the Sialic Acid-Binding Receptors Siglec-G and CD22 , 2011, Front. Immun..

[15]  C. Pui,et al.  A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL) , 2011 .

[16]  Xiaomin Lu,et al.  Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2 , 2011 .

[17]  D. Goldenberg,et al.  Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies , 2011, Molecular Cancer Therapeutics.

[18]  I. Pastan,et al.  Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. , 2011, Cancer research.

[19]  A. Ricart.  Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin , 2011, Clinical Cancer Research.

[20]  P. Kurtin,et al.  Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. , 2011, Blood.

[21]  I. Pastan,et al.  Immunotoxins with decreased immunogenicity and improved activity , 2011, Leukemia & lymphoma.

[22]  J. Paulson,et al.  CD22 Is a Recycling Receptor That Can Shuttle Cargo between the Cell Surface and Endosomal Compartments of B Cells , 2011, The Journal of Immunology.

[23]  V. Ramakrishnan,et al.  Investigational antibody-drug conjugates for hematological malignancies , 2011, Expert opinion on investigational drugs.

[24]  Bin-Bing S. Zhou,et al.  Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP , 2011, Cancer Chemotherapy and Pharmacology.

[25]  M. Mitka.  Oversight of fast-track drug approval by FDA stuck in low gear, critics say. , 2010, JAMA.

[26]  J. Cerhan,et al.  Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Goozner.  FDA increases focus on postmarketing studies. , 2010, Journal of the National Cancer Institute.

[28]  D. Huglo,et al.  High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A. Ebens,et al.  Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma , 2010, Leukemia.

[30]  James C Paulson,et al.  In vivo targeting of B-cell lymphoma with glycan ligands of CD22. , 2010, Blood.

[31]  J. Tuscano,et al.  Efficacy, Biodistribution, and Pharmacokinetics of CD22-Targeted Pegylated Liposomal Doxorubicin in a B-cell Non–Hodgkin's Lymphoma Xenograft Mouse Model , 2010, Clinical Cancer Research.

[32]  S. Steinberg,et al.  Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial , 2010, Clinical Cancer Research.

[33]  J. Cerhan,et al.  Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Radich,et al.  Southwest Oncology Group Study S0910: A Phase 2 Trial of Clofarabine/ Cytarabine/ Epratuzumab for Relapsed/ Refractory Acute Lymphocytic Leukemia. , 2009 .

[35]  R. O’Donnell,et al.  Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts , 2009, Cancer Immunology, Immunotherapy.

[36]  E. L. Prak,et al.  Developmental Acquisition of the Lyn-CD22-SHP-1 Inhibitory Pathway Promotes B Cell Tolerance1 , 2009, The Journal of Immunology.

[37]  R. O’Donnell,et al.  Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD) , 2009, Investigational New Drugs.

[38]  J. Leonard,et al.  Durable complete responses from therapy with combined epratuzumab and rituximab , 2008, Cancer.

[39]  M. Czuczman,et al.  Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab) , 2008, Clinical Cancer Research.

[40]  S. Hunger,et al.  Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Borowitz,et al.  Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Kenneth G. C. Smith,et al.  CD22: an inhibitory enigma , 2008, Immunology.

[43]  N. Damle,et al.  Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia , 2007, Leukemia.

[44]  J. Pagel,et al.  Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas. , 2007, Cancer research.

[45]  W. Wakarchuk,et al.  Distinct Endocytic Mechanisms of CD22 (Siglec-2) and Siglec-F Reflect Roles in Cell Signaling and Innate Immunity , 2007, Molecular and Cellular Biology.

[46]  C. Bennett,et al.  Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. , 2007, Leukemia research.

[47]  A. Cesano,et al.  Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. , 2007, Molecular immunology.

[48]  D. Goldenberg.  Epratuzumab in the therapy of oncological and immunological diseases , 2006, Expert review of anticancer therapy.

[49]  Jay K. Nathan,et al.  High-Affinity Ligand Probes of CD22 Overcome the Threshold Set by cis Ligands to Allow for Binding, Endocytosis, and Killing of B Cells1 , 2006, The Journal of Immunology.

[50]  T. Lister,et al.  Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  R. Watanabe,et al.  B Cell Antigen Receptor and CD40 Differentially Regulate CD22 Tyrosine Phosphorylation1 , 2006, The Journal of Immunology.

[52]  J. Leonard,et al.  Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  L. Stenberg,et al.  Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab , 2005, Clinical Cancer Research.

[54]  M. Hibbs,et al.  Lyn tyrosine kinase: accentuating the positive and the negative. , 2005, Immunity.

[55]  P. Solal-Céligny,et al.  Follicular lymphoma international prognostic index , 2006, Blood.

[56]  M. Fujimoto,et al.  CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms , 2004, Nature Immunology.

[57]  J. Leonard,et al.  Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma , 2004, Clinical Cancer Research.

[58]  T. Town,et al.  Neuronal expression of CD22: Novel mechanism for inhibiting microglial proinflammatory cytokine production , 2004, Glia.

[59]  M. Reth,et al.  B cell defects in SLP65/BLNK‐deficient mice can be partially corrected by the absence of CD22, an inhibitory coreceptor for BCR signaling , 2003, European journal of immunology.

[60]  A. Alavi,et al.  Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[61]  J. Leonard,et al.  Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  K. Lamborn,et al.  Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. , 2003, Blood.

[63]  G. Griffiths,et al.  90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[64]  Theresa M Allen,et al.  Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. , 2002, Cancer research.

[65]  I. Pastan,et al.  Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[66]  Kenichi Watanabe,et al.  Difference in CD22 molecules in human B cells and basophils. , 2002, Experimental hematology.

[67]  J. Leonard,et al.  Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). , 2002, Seminars in oncology.

[68]  E. Clark,et al.  CD22 Regulates B Cell Receptor-mediated Signals via Two Domains That Independently Recruit Grb2 and SHP-1* , 2001, The Journal of Biological Chemistry.

[69]  W. Wilson,et al.  Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. , 2001, The New England journal of medicine.

[70]  D. Goldenberg,et al.  Generation of a high‐producing clone of a humanized anti‐B‐cell lymphoma monoclonal antibody (hLL2) , 1997, Cancer.

[71]  S. Sato,et al.  CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. , 1997, Annual review of immunology.

[72]  I. Pastan,et al.  Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies. , 1996, Bioconjugate chemistry.

[73]  R. Levy,et al.  Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[74]  A. Miller,et al.  Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand , 1995, The Journal of experimental medicine.

[75]  D. Goldenberg,et al.  Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma. , 1994, Hybridoma.

[76]  I. Bernstein,et al.  Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. , 1993, The New England journal of medicine.

[77]  90 Y-DOTA-hLL2: An Agent for Radioimmunotherapy of Non-Hodgkin’s Lymphoma R adioimmunotherapy for hematologic malignancies , 2022 .